Review Article

You have full text access to this OnlineOpen article

Where do we stand with hepatoblastoma?

A review

  1. J. Marco Schnater M.D.1,2,3,
  2. S. Eleonore Köhler Ph.D.2,
  3. Wouter H. Lamers M.D.3,
  4. Dietrich von Schweinitz M.D.2,
  5. Daniël C. Aronson M.D.1,†,*

Article first published online: 16 JUL 2003

DOI: 10.1002/cncr.11585

Issue

Cancer

Cancer

Volume 98, Issue 4, pages 668–678, 15 August 2003

Additional Information

How to Cite

Schnater, J. M., Köhler, S. E., Lamers, W. H., von Schweinitz, D. and Aronson, D. C. (2003), Where do we stand with hepatoblastoma?. Cancer, 98: 668–678. doi: 10.1002/cncr.11585

Author Information

  1. 1

    Pediatric Surgical Center of Amsterdam, Emma Children's Hospital AMC, Academic Medical Center, Amsterdam, The Netherlands

  2. 2

    Department of Pediatric Surgery, University Children's Hospital, Basel, Switzerland

  3. 3

    AMC Liver Center, Academic Medical Center, Amsterdam, The Netherlands

  1. †

    Fax: (011) 31 20566-9287

*Pediatric Surgical Center of Amsterdam, Emma Children's Hospital AMC, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands

Publication History

  1. Issue published online: 1 AUG 2003
  2. Article first published online: 16 JUL 2003
  3. Manuscript Accepted: 19 MAY 2003
  4. Manuscript Revised: 27 APR 2003
  5. Manuscript Received: 31 DEC 2002

Funded by

  • TerMeulen Fund
  • Royal Netherlands Academy of Arts and Sciences

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (195K)

REFERENCES

  • 1
    Misick OS. A case of teratoma hepatis. J Pathol Bacteriol. 1898; 5: 128–137.
    Direct Link:
  • 2
    Exelby PR, Filler RM, Grosfeld JL. Liver tumors in children in the particular reference to hepatoblastoma and hepatocellular carcinoma: American Academy of Pediatrics Surgical Section Survey—1974. J Pediatr Surg. 1975; 10: 329–337.
  • 3
    Vos A. Primary liver tumours in children. Eur J Surg Oncol. 1995; 21: 101–105.
  • 4
    Raney B. Hepatoblastoma in children: a review. J Pediatr Hematol Oncol. 1997; 19: 418–422.
  • 5
    Perilongo G, Shafford EA. Liver tumours. Eur J Cancer. 1999; 35: 953–958; discussion 958–959.
  • 6
    Herzog CE, Andrassy RJ, Eftekhari F. Childhood cancers: hepatoblastoma. Oncologist. 2000; 5: 445–453.
  • 7
    Mann JR, Kasthuri N, Raafat F, et al. Malignant hepatic tumours in children: incidence, clinical features and aetiology. Paediatr Perinat Epidemiol. 1990; 4: 276–289.
    Direct Link:
  • 8
    Clatworthy HW, Schiller M, Grosfeld JL. Primary liver tumors in infancy and childhood. 41 cases variously treated. Arch Surg. 1974; 109: 143–147.
  • 9
    Ikeda H, Matsuyama S, Tanimura M. Association between hepatoblastoma and very low birth weight: a trend or a chance [see comments]? J Pediatr. 1997; 130: 557–560. Comment in: J Pediatr. 1997;130:516–517; J Pediatr. 1998;132:750; J Pediatr. 1998;133:585–586.
  • 10
    Feusner J, Plaschkes J. Hepatoblastoma and low birth weight: a trend or chance observation? Med Pediatr Oncol. 2002; 39: 508–509.
    Direct Link:
  • 11
    Haas OA, Zoubek A, Grumayer ER, Gadner H. Constitutional interstitial deletion of 11p11 and pericentric inversion of chromosome 9 in a patient with Wiedemann–Beckwith syndrome and hepatoblastoma. Cancer Genet Cytogenet. 1986; 23: 95–104.
  • 12
    Steenman M, Westerveld A, Mannens M. Genetics of Beckwith–Wiedemann syndrome-associated tumors: common genetic pathways. Genes Chromosomes Cancer. 2000; 28: 1–13.
    Direct Link:
  • 13
    Swarts S, Wisecarver J, Bridge JA. Significance of extra copies of chromosome 20 and the long arm of chromosome 2 in hepatoblastoma. Cancer Genet Cytogenet. 1996; 91: 65–67.
  • 14
    Schneider NR, Cooley LD, Finegold MJ, Douglass EC, Tomlinson GE. The first recurring chromosome translocation in hepatoblastoma: der(4)t(1;4)(q12;q34). Genes Chromosomes Cancer. 1997; 19: 291–294.
    Direct Link:
  • 15
    Ma SK, Cheung AN, Choy C, et al. Cytogenetic characterization of childhood hepatoblastoma. Cancer Genet Cytogenet. 2000; 119: 32–36.
  • 16
    Parada LA, Limon J, Iliszko M, et al. Cytogenetics of hepatoblastoma: further characterization of 1q rearrangements by fluorescence in situ hybridization: an international collaborative study. Med Pediatr Oncol. 2000; 34: 165–170.
    Direct Link:
  • 17
    Weber RG, Pietsch T, von Schweinitz D, Lichter P. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol. 2000; 157: 571–578.
  • 18
    Ali W, Savasan S, Rabah R, Mohamed AN. Cytogenetic findings in two new cases of hepatoblastoma. Cancer Genet Cytogenet. 2002; 133: 179–182.
  • 19
    von Schweinitz D, Kraus JA, Albrecht S, Koch A, Fuchs J, Pietsch T. Prognostic impact of molecular genetic alterations in hepatoblastoma. Med Pediatr Oncol. 2002; 38: 104–108.
    Direct Link:
  • 20
    Kraus JA, Albrecht S, Wiestler OD, von Schweinitz D, Pietsch T. Loss of heterozygosity on chromosome 1 in human hepatoblastoma. Int J Cancer. 1996; 67: 467–471.
    Direct Link:
  • 21
    Albrecht S, von Schweinitz D, Waha A, Kraus JA, von Deimling A, Pietsch T. Loss of maternal alleles on chromosome arm 11p in hepatoblastoma. Cancer Res. 1994; 54: 5041–5044.
  • 22
    Hartmann W, Waha A, Koch A, et al. p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19. Am J Pathol. 2000; 157: 1393–1403.
  • 23
    Debuire B, Paterlini P, Pontisso P, Basso G, May E. Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene. 1993; 8: 2303–2306.
  • 24
    Chen TC, Hsieh LL, Kuo TT. Absence of p53 gene mutation and infrequent overexpression of p53 protein in hepatoblastoma. J Pathol. 1995; 176: 243–247.
    Direct Link:
  • 25
    Kusafuka T, Fukuzawa M, Oue T, Komoto Y, Yoneda A, Okada A. Mutation analysis of p53 gene in childhood malignant solid tumors. J Pediatr Surg. 1997; 32: 1175–1180.
  • 26
    Zerbini MC, Sredni ST, Grier H, et al. Primary malignant epithelial tumors of the liver in children: a study of DNA content and oncogene expression. Pediatr Dev Pathol. 1998; 1: 270–280.
  • 27
    Habrand JL, Nehme D, Kalifa C, et al. Is there a place for radiation therapy in the management of hepatoblastomas and hepatocellular carcinomas in children [see comments]? Int J Radiat Oncol Biol Phys. 1992; 23: 525–531. Comment in: Int J Radiat Oncol Biol Phys. 1992;23:675–676.
  • 28
    von Schweinitz D. Identification of risk groups in hepatoblastoma—another step in optimising therapy [editorial]. Eur J Cancer. 2000; 6: 1343–1346.
  • 29
    Ruck P, Xiao JC, Pietsch T, von Schweinitz D, Kaiserling E. Hepatic stem-like cells in hepatoblastoma: expression of cytokeratin 7, albumin and oval cell associated antigens detected by OV-1 and OV-6. Histopathology. 1997; 31: 324–329.
    Direct Link:
  • 30
    Vassey CJ, De La Hall PM. Hepatic stem cells: a review. Pathology. 2001; 33: 130–141.
  • 31
    Ruck P, Xiao JC. Stem-like cells in hepatoblastoma. Med Pediatr Oncol. 2002; 39: 504–507.
    Direct Link:
  • 32
    Zimmermann A. Hepatoblastoma with cholangioblastic features (“cholangioblastic hepatoblastoma”) and other liver tumors with bimodal differentiation in young patients. Med Pediatr Oncol. 2002; 39: 487–491.
    Direct Link:
  • 33
    von Schweinitz D, Schmidt D, Fuchs J, Welte K, Pietsch T. Extramedullary hematopoiesis and intratumoral production of cytokines in childhood hepatoblastoma. Pediatr Res. 1995; 38: 555–563.
  • 34
    von Schweinitz D, Hadam MR, Welte K, Mildenberger H, Pietsch T. Production of interleukin-1 beta and interleukin-6 in hepatoblastoma. Int J Cancer. 1993; 53: 728–734.
    Direct Link:
  • 35
    Miyazaki M, Gohda E, Tsuboi S, et al. Human hepatocyte growth factor stimulates the growth of HUH-6 clone 5 human hepatoblastoma cells. Cell Biol Int Rep. 1992; 16: 145–154.
  • 36
    von Schweinitz D, Faundez A, Teichmann B, et al. Hepatocyte growth-factor-scatter factor can stimulate post-operative tumor-cell proliferation in childhood hepatoblastoma. Int J Cancer. 2000; 85: 151–159.
  • 37
    von Schweinitz D, Fuchs J, Gluer S, Pietsch T. The occurrence of liver growth factor in hepatoblastoma. Eur J Pediatr Surg. 1998; 8: 133–136.
  • 38
    Hughes LJ, Michels VV. Risk of hepatoblastoma in familial adenomatous polyposis. Am J Med Genet. 1992; 43: 1023–1025.
    Direct Link:
  • 39
    Oda H, Imai Y, Nakatsuru Y, Hata J, Ishikawa T. Somatic mutations of the APC gene in sporadic hepatoblastomas. Cancer Res. 1996; 56: 3320–3323.
  • 40
    Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res. 1999; 59: 269–273.
  • 41
    Anna CH, Sills RC, Foley JF, Stockton PS, Ton TV, Devereux TR. Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam. Cancer Res. 2000; 60: 2864–2868.
  • 42
    Udatsu Y, Kusafuka T, Kuroda S, Miao J, Okada A. High frequency of beta-catenin mutations in hepatoblastoma. Pediatr Surg Int. 2001; 17: 508–512.
  • 43
    Park WS, Oh RR, Park JY, et al. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol. 2001; 193: 483–490.
    Direct Link:
  • 44
    Takayasu H, Horie H, Hiyama E, et al. Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res. 2001; 7: 901–908.
  • 45
    Monga SP, Mars WM, Pediaditakis P, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. Cancer Res. 2002; 62: 2064–2071.
  • 46
    Hartley AL, Birch JM, Kelsey AM, Jones PH, Harris M, Blair V. Epidemiological and familial aspects of hepatoblastoma. Med Pediatr Oncol. 1990; 18: 103–109.
    Direct Link:
  • 47
    Perilongo G, Brown J, Shafford E, et al. Hepatoblastoma presenting with lung metastases. Cancer. 2000; 89: 1845–1853.
    Direct Link:
  • 48
    Miyagi J, Kobayashi S, Kojo N, Watanabe M, Kuramoto S, Hirose F. Brain metastasis of hepatoblastoma—a case report and review of literature. No Shinkei Geka (Neurol Surg). 1984; 12: 753–758.
  • 49
    Endo EG, Walton DS, Albert DM. Neonatal hepatoblastoma metastatic to the choroid and iris. Arch Ophthalmol. 1996; 114: 757–761.
  • 50
    Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001; 98: 2720–2725.
  • 51
    Lack EE, Neave C, Vawter GF. Hepatoblastoma. A clinical and pathologic study of 54 cases. Am J Surg Pathol. 1982; 6: 693–705.
  • 52
    de Campo M, de Campo JF. Ultrasound of primary hepatic tumours in childhood. Pediatr Radiol. 1988; 19: 19–24.
  • 53
    Siegel MJ, Herman TE. Periportal low attenuation at CT in childhood. Radiology. 1992; 183: 685–688.
  • 54
    Archer D, Babyn P, Gilday D, Greenberg MA. Potentially misleading bone scan findings in patients with hepatoblastoma. Clin Nucl Med. 1993; 18: 1026–1031.
  • 55
    von Schweinitz D, Burger D, Mildenberger H. Is laparatomy the first step in treatment of childhood liver tumors? The experience from the German Cooperative Pediatric Liver Tumor Study HB-89. Eur J Pediatr Surg. 1994; 4: 82–86.
  • 56
    Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000; 18: 2665–2675.
  • 57
    Bravo AA, Sheth SG, Chopra S. Review articles: liver biopsy. N Engl J Med. 2001; 344: 495–500.
  • 58
    Takvorian P, Floret D, Valette PJ, Bouffet E, Pradon M. Hepatic rupture after puncture biopsy: value of embolization. Apropos of a case with hepatoblastoma. Pediatrie. 1988; 43: 531–533.
  • 59
    MacKinlay EL, Pritchard J. A common language for childhood liver tumours. Pediatr Surg Int. 1992; 7: 325–326.
  • 60
    SobinLH, WittekindC, editors. TNM classification of malignant tumors, 5th edition. New York: John Wiley & Sons, 1997.
  • 61
    Morita K, Okabe I, Uchino J, et al. The proposed Japanese TNM classification of primary liver carcinoma in infants and children. Jpn J Clin Oncol. 1983; 13: 361–369.
  • 62
    Ortega JA, Krailo MD, Haas JE, et al. Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: a report from the Children's Cancer Study Group. J Clin Oncol. 1991; 9: 2167–2176.
  • 63
    Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1993; 11: 96–99.
  • 64
    von Schweinitz D, Hecker H, Schmidt-von-Arndt G, Harms D. Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer. 1997; 74: 593–599.
    Direct Link:
  • 65
    Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma—results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer. 2000; 36: 1418–1425.
  • 66
    Plaschkes J. Proceedings of an international research workshop on pediatric liver tumours, 18–20 March, 1999, Berne, Switzerland. Into the year 2000. Med Pediatr Oncol. 2001; 36: 380–382.
    Direct Link:
  • 67
    Rowland JM. Hepatoblastoma: assessment of criteria for histologic classification. Med Pediatr Oncol. 2002; 39: 478–483.
    Direct Link:
  • 68
    Ishak KG, Glunz PR. Hepatoblastoma and hepatocarcinoma in infancy and childhood. Report of 47 cases. Cancer. 1967; 20: 396–422.
    Direct Link:
  • 69
    Kasai M, Watanabe I. Histologic classification of liver-cell carcinoma in infancy and childhood and its clinical evaluation. A study of 70 cases collected in Japan. Cancer. 1970; 25: 551–563.
    Direct Link:
  • 70
    Dehner LP, Manivel JC. Hepatoblastoma: an analysis of the relationship between morphologic subtypes and prognosis. Am J Pediatr Hematol Oncol. 1988; 10: 301–307.
  • 71
    Gonzalez-Crussi F, Upton MP, Maurer HS. Hepatoblastoma. Attempt at characterization of histologic subtypes. Am J Surg Pathol. 1982; 6: 599–612.
  • 72
    Stocker JT. Hepatoblastoma. Semin Diagn Pathol. 1994; 11: 136–143.
  • 73
    Fasano M, Theise ND, Nalesnik M, et al. Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker, hepatocyte paraffin 1, and the polyclonal anti-carcinoembryonic antigen. Mod Pathol. 1998; 11: 934–938.
  • 74
    Fuchs J, Schmidt D, Pietsch T, Miller K, von Schweinitz D. Successful transplantation of human hepatoblastoma into immunodeficient mice. J Pediatr Surg. 1996; 31: 1241–1246.
  • 75
    Haas JE, Muczynski KA, Krailo M, et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer. 1989; 64: 1082–1095.
    Direct Link:
  • 76
    Conran RM, Hitchcock CL, Waclawiw MA, Stocker JT, Ishak KG. Hepatoblastoma: the prognostic significance of histologic type. Pediatr Pathol. 1992; 12: 167–183.
  • 77
    von Schweinitz D, Wischmeyer P, Leuschner I, et al. Clinico-pathological criteria with prognostic relevance in hepatoblastoma. Eur J Cancer. 1994; 8: 1052–1058.
  • 78
    Haas JE, Feusner JH, Finegold MJ. Small cell undifferentiated histology in hepatoblastoma may be unfavorable. Cancer. 2001; 92: 3130–134.
    Direct Link:
  • 79
    Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin and delayed surgery for childhood hepatoblastoma a successful approach. Results of the first prospective study of the International Society of Pediatric Oncology (SIOP)—SIOPEL 1. J Clin Oncol. 2000; 18: 3819–3828.
  • 80
    Schnater JM, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma. Results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group (SIOPEL-1). Cancer. 2002; 94: 1111–1120.
  • 81
    Evans AE, Land VJ, Newton WA, Randolph JG, Sather HN, Tefft M. Combination chemotherapy (vincristine, Adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma. Cancer. 1982; 50: 821–826.
    Direct Link:
  • 82
    Douglass EC, Green AA, Wrenn E, Champion J, Shipp M, Pratt CB. Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma. Med Pediatr Oncol. 1985; 13: 187–190.
    Direct Link:
  • 83
    Reynolds M. Conversion of unresectable to resectable hepatoblastoma and long-term follow-up study. World J Surg. 1995; 19: 814–816.
  • 84
    Warmann S, Hunger M, Teichmann B, Flemming P, Gratz KF, Fuchs J. The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model. Cancer. 2002; 95: 1795–1801.
    Direct Link:
  • 85
    Warmann S, Gohring G, Teichmann B, Geerlings H, Fuchs J. MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro. J Pediatr Surg. 2002; 37: 1579–1584.
  • 86
    Advani R, Visani G, Milligan D, et al. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Adv Exp Med Biol. 1999; 457: 47–56.
  • 87
    Kaye SB. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol. 1998; 10 (Suppl 1): S15–S19.
  • 88
    Stein WD. Reversers of the multidrug resistance transporter P-glycoprotein. Curr Opin Invest Drugs. 2002; 3: 812–817.
  • 89
    Starzl TE, Groth CG, Brettschneider L, et al. Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery. 1968; 63: 549–563.
  • 90
    Koneru B, Flye MW, Busuttil RW, et al. Liver transplantation for hepatoblastoma. The American experience. Ann Surg. 1991; 213: 118–121.
  • 91
    Achilleos OA, Buist LJ, Kelly DA, et al. Unresectable hepatic tumors in childhood and the role of liver transplantation. J Pediatr Surg. 1996; 31: 1563–1567.
  • 92
    Otte JB, Aronson D, Vraux H, et al. Preoperative chemotherapy, major liver resection, and transplantation for primary malignancies in children. Transplant Proc. 1996; 28: 2393–2394.
  • 93
    Al-Qabandi W, Jenkinson HC, Buckels JA, Mayer AD, McKiernan P, Morland B, et al. Orthotopic liver transplantation for unresectable hepatoblastoma: a single center's experience. J Pediatr Surg. 1999; 34: 1261–1264.
  • 94
    Pichlmayr R, Weimann A, Tusch G, Schlitt HJ. Indications and role of liver transplantation for malignant tumors. Oncologist. 1997; 2: 164–170.
  • 95
    Reyes JD, Carr B, Dvorchik I, et al. Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pediatr. 2000; 136: 795–804.
  • 96
    Otte JB, Arouson DC, Brown J, et al. Liver transplantation for hepatoblastoma. Results from the International Society of Pediatric Oncology (SIOP) Study SIOPEL-1 and review of the world experience. Med Pediatr Oncol. In press.
  • 97
    Han YM, Park HH, Lee JM, et al. Effectiveness of preoperative transarterial chemoembolization in presumed inoperable hepatoblastoma. J Vasc Interv Radiol. 1999; 10: 1275–1280.
  • 98
    Takayama T, Makuuchi M, Takayasu K, et al. Resection after intraarterial chemotherapy of a hepatoblastoma originating in the caudate lobe. Surgery. 1990; 107: 231–235.
  • 99
    Elias D, Lasser P, Rougier P, Ducreux M, Bognel C, Roche A. Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. J Am Coll Surg. 1995; 180: 213–219.
  • 100
    Malogolowkin MH, Stanley P, Steele DA, Ortega JA. Feasibility and toxicity of chemoembolization for children with liver tumors. J Clin Oncol. 2000; 18: 1279–1284.
  • 101
    Healey EA, Shamberger RC, Grier HE, Loeffler JS, Tarbell NJ. A 10-year experience of pediatric brachytherapy. Int J Radiat Oncol Biol Phys. 1995; 32: 451–455.
  • 102
    Kanai F, Lan KH, Shiratori Y, et al. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 1997; 57: 461–465.
  • 103
    Cao G, Kuriyama S, Gao J, et al. Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter. Eur J Cancer. 2001; 37: 140–147.
  • 104
    Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK, von Schweinitz D. Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest. 1996; 74: 809–818.
  • 105
    Fuchs J, Wenderoth M, von Schweinitz D, Haindl J, Leuschner I. Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma. Cancer. 1998; 83: 2400–2407.
    Direct Link:
  • 106
    Schnater JM, Köhler SE, Bruder E, et al. Ein Tiermodell für das humane Hepatoblastom. In: SiewertJR, editor. Chirurgisches Forum 2002 für experimentelle und klinische Forschung, Volume 31, 1st edition. Berlin: Springer-Verlag, 2002: 543–537.
  • 107
    van Tornout JM, Buckley JD, Quinn JJ, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group. J Clin Oncol. 1997; 15: 1190–1197.
View Full Article (HTML) Get PDF (195K)